More than just animals. More than just technology.

At Bioceltix, we believe that humans and their animal companions share the same long and fascinating life journey. This partnership means we have a responsibility to foster their health and well-being. To care for our animals, as they care for us. And make our shared world more complete.

Bioceltix is a biotechnology company built by a team of scientists who recognized the need for a new perspective on veterinary medicine.

With companion animals in mind, we develop innovative medicinal products that meet the same high standards as those created for humans. We are advancing pioneering veterinary biologics that harness the immunomodulatory properties of mesenchymal stem cells (MSCs). Our focus is on inflammatory and autoimmune conditions, addressing the underlying cause, not just the symptoms.

The technology we have developed, combined with dedicated production lines and pharmaceutical-grade quality standards, gives us a unique advantage in the emerging field of veterinary biotechnology.

Every day we move closer to goals that will redefine the future of veterinary care. Guided by science and inspired by our passion and love for four-legged companions, we pursue our mission with determination.

Caring for them; As they care for us: Our portfolio

BCX-CM-J

An allogeneic stem cell-based medicinal product for the treatment of osteoarthritis in dogs.

BCX-CM-AD

An allogeneic stem cell-based medicinal product for the treatment of atopic dermatitis in dogs.

BCX-EM

An allogeneic stem cell-based medicinal product developed for the treatment of osteoarthritis in horses.

BCX-CM-Sec

A research project aimed at developing a cell-free biological drug effective in treating atopic dermatitis in dogs.

Innovating for better health

BCX in brief

Mesenchymal stem cells (MSC) as the active pharmaceutical ingredient

Allogeneic therapy (one donor – many recipients)

Immunomodulatory properties of the cells, with potential for both causal and symptomatic treatment

Proven efficacy and safety of the products under development

Advanced development stage of flagship medicinal products, including the initiation of marketing authorisation with the European Medicines Agency (EMA)

Stem cell manufacturing facility operating under pharmaceutical cGMP quality standards

Driven by passion and love for our four-legged companions

Investor Relations

Discover how you can help bring innovative MSC-based biologic therapies to companion animals

This site is registered on wpml.org as a development site. Switch to a production site key to remove this banner.